<?phpxml version="1.0" encoding="utf-8"?>
<rss version="2.0" 
xmlns:content="http://purl.org/rss/1.0/modules/content/"
xmlns:wfw="http://wellformedweb.org/CommentAPI/"
xmlns:dc="http://purl.org/dc/elements/1.1/"
>
<channel>
<title>The Meetingpoint at Slavyanski.net / changeweeder / Upvoted</title>
<link>https://slavyanski.net/sb2020</link>
<description>Your Source for Social News and Networking</description>
<pubDate>Sat, 05 Sep 2020 02:51:45 +0000</pubDate>
<language>en</language>
<item>
	<title><![CDATA[To mediate ADCC in vitro [9, 17, 23]. Although the contribution of ADCC activity]]></title>
	<link>https://slavyanski.net/sb2020/story.php?title=to-mediate-adcc-in-vitro-9-17-23-although-the-contribution-of-adcc-activity-9</link>
	<source url="https://slavyanski.net/sb2020/story.php?title=to-mediate-adcc-in-vitro-9-17-23-although-the-contribution-of-adcc-activity-9"><![CDATA[To mediate ADCC in vitro [9, 17, 23]. Although the contribution of ADCC activity]]></source>
	<description><![CDATA[To mediate ADCC in vitro [9, 17, 23]. Although the contribution of ADCC activity to clinical efficacy is unclear, it is important to characterize all activities of the candidate mAb, especially those that can be affected by differences in post-translational modifications, such as glycosylation. The ability of ABP 501 to induce ADCC was assessed using MT-3 cells as target cells, and NK-92M1 cells s ]]></description>
	<pubDate>Sat, 05 Sep 2020 02:51:45 +0000</pubDate>
	<author>changeweeder</author>
	<category>News</category>
	<votes>1</votes>
	<guid>https://slavyanski.net/sb2020/story.php?title=to-mediate-adcc-in-vitro-9-17-23-although-the-contribution-of-adcc-activity-9</guid>
</item>

<item>
	<title><![CDATA[To mediate ADCC in vitro [9, 17, 23]. Although the contribution of ADCC activity]]></title>
	<link>https://slavyanski.net/sb2020/story.php?title=to-mediate-adcc-in-vitro-9-17-23-although-the-contribution-of-adcc-activity-6</link>
	<source url="https://slavyanski.net/sb2020/story.php?title=to-mediate-adcc-in-vitro-9-17-23-although-the-contribution-of-adcc-activity-6"><![CDATA[To mediate ADCC in vitro [9, 17, 23]. Although the contribution of ADCC activity]]></source>
	<description><![CDATA[To mediate ADCC in vitro [9, 17, 23]. Although the contribution of ADCC activity to clinical efficacy is unclear, it is important to characterize all activities of the candidate mAb, especially those that can be affected by differences in post-translational modifications, such as glycosylation. The ability of ABP 501 to induce ADCC was assessed using MT-3 cells as target cells, and NK-92M1 cells s ]]></description>
	<pubDate>Sat, 05 Sep 2020 02:51:15 +0000</pubDate>
	<author>changeweeder</author>
	<category></category>
	<votes>1</votes>
	<guid>https://slavyanski.net/sb2020/story.php?title=to-mediate-adcc-in-vitro-9-17-23-although-the-contribution-of-adcc-activity-6</guid>
</item>

<item>
	<title><![CDATA[Of action. This is often an iterative process in which analytical]]></title>
	<link>https://slavyanski.net/sb2020/story.php?title=of-action-this-is-often-an-iterative-process-in-which-analytical</link>
	<source url="https://slavyanski.net/sb2020/story.php?title=of-action-this-is-often-an-iterative-process-in-which-analytical"><![CDATA[Of action. This is often an iterative process in which analytical]]></source>
	<description><![CDATA[Of action. This is often an iterative process in which analytical similarity is tested and then further explored in preclinical biofunctional tests to determine whether minor differences, should they exist, result in differences in the biological activity of the molecule (Fig. 1). Confidence in the similarity of the molecule at this foundational step allows for a reduction in residual uncertainty  ]]></description>
	<pubDate>Thu, 03 Sep 2020 17:09:35 +0000</pubDate>
	<author>changeweeder</author>
	<category>News</category>
	<votes>1</votes>
	<guid>https://slavyanski.net/sb2020/story.php?title=of-action-this-is-often-an-iterative-process-in-which-analytical</guid>
</item>

</channel>
</rss>
